Vitamin D treatment in primary hyperparathyroidism

Current Drug Safety

Volumn 6, Issue 2, 2011, Pages 100-107

  Rolighed, Lars ^a   Bollerslev, Jens ^b,c   Mosekilde, Leif ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Primary hyperparathyroidism; Review; Vitamin D insufficiency; Vitamin D treatment

Indexed keywords

24,25 DIHYDROXYVITAMIN D; 25 HYDROXYVITAMIN D; ALFACALCIDOL; CALCITRIOL; CALCIUM; COLECALCIFEROL; ERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; VITAMIN D;

ABSENCE OF SIDE EFFECTS; BONE MASS; BONE TURNOVER; CALCIUM HOMEOSTASIS; CALCIUM URINE LEVEL; CARDIOVASCULAR RISK; DRUG DOSE INCREASE; DRUG SAFETY; HUMAN; NONHUMAN; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; SIDE EFFECT; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN METABOLISM;

EID: 79958208739     PISSN: 15748863     EISSN: 15748863     Source Type: Journal    
DOI: 10.2174/157488611795684613     Document Type: Review

References (77)

1. Eastell R, Arnold A, Brandi ML, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009; 94: 340-350.
2. Parfitt AM. The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone diseases. II. PTH and bone cells: bone turnover and plasma calcium regulation. Metabolism 1976; 25: 909-955
3. Parfitt AM. Bone and plasma calcium homeostasis. Bone 1987; 8 (Suppl 1): S1-S8.
4. Rao DS, Wilson RJ, Kleerekoper M, Parfitt AM. Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. J Clin Endocrinol Metab 1988; 67: 1294-1298.
5. Peacock M, Bilezikian JP, Bolognese MA, et al. Cinacalcet HCl Reduces Hypercalcemia in Primary Hyperparathyroidism across a Wide Spectrum of Disease Severity. J Clin Endocrinol Metab 2011; 96: E9-E18.
6. Kumar R, Thompson JR. The regulation of parathyroid hormone secretion and synthesis. J Am Soc Nephrol 2011; 22: 216-224.
7. Hofer AM, Brown EM. Extracellular calcium sensing and signalling. Nat Rev Mol Cell Biol 2003; 4: 530-538.
8. Bilezikian JP, Khan AA, Potts JT, Jr. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 2009; 94: 335-339.
9. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001; 22: 477-501.
10. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, wson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006; 84: 18-28
11. Moosgaard B, Vestergaard P, Heickendorff L, Melsen F, Christiansen P, Mosekilde L. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf) 2005; 63: 506-513.
12. Grey A, Lucas J, Horne A, Gamble G, Davidson JS, Reid IR. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab 2005; 90: 2122-2126.
13. Silverberg SJ Vitamin D deficiency and primary hyperparathyroidism. J Bone Miner Res 2007; 22 Suppl 2: V100-V104.
14. Clements MR, Davies M, Fraser DR, Lumb GA, Mawer EB, Adams PH. Metabolic inactivation of vitamin D is enhanced in primary hyperparathyroidism. Clin Sci (Lond) 1987; 73: 659-664.
15. Clements MR, Davies M, Hayes ME, et al. The role of 1,25-dihydroxyvitamin D in the mechanism of acquired vitamin D deficiency. Clin Endocrinol (Oxf) 1992; 37: 17-27.
16. Boudou P, Ibrahim F, Cormier C, Sarfati E, Souberbielle JC. A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism. J Endocrinol Invest 2006; 29: 511-515.
17. Rao DS, Agarwal G, Talpos GB, et al. Role of vitamin D and calcium nutrition in disease expression and parathyroid tumor growth in primary hyperparathyroidism: a global perspective. J Bone Miner Res 2002; 17 (Suppl 2): N75-N80.
18. Mosekilde L. Primary hyperparathyroidism and the skeleton. Clin Endocrinol (Oxf) 2008; 69: 1-19.
19. Moosgaard B, Vestergaard P, Heickendorff L, Melsen F, Christiansen P, Mosekilde L. Plasma 25-hydroxyvitamin D and not 1,25-dihydroxyvitamin D is associated with parathyroid adenoma secretion in primary hyperparathyroidism: a cross-sectional study. Eur J Endocrinol 2006; 155: 237-244.
20. Brown AJ, Dusso A, Slatopolsky E Vitamin D. Am J Physiol 1999; 277: F157-F175.
21. Amstrup AK, Rejnmark L, Vestergaard P, et al. Vitamin D status, physical performance and body mass in patients surgically cured for primary hyperparathyroidism compared with healthy controls -a cross-sectional study. Clin Endocrinol (Oxf) 2011; 74(1): 130-136.
22. Bolland MJ, Grey AB, Ames RW, Horne AM, Gamble GD, Reid IR. Fat mass is an important predictor of parathyroid hormone levels in postmenopausal women. Bone 2006; 38: 317-321.
23. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000; 72: 690-693.
24. Lin E, rmstrong-Moore D, Liang Z, et al. Contribution of Adipose Tissue to Plasma 25-Hydroxyvitamin D Concentrations During Weight Loss Following Gastric Bypass Surgery. Obesity (Silver Spring) 2011; 19(3): 588-594.
25. Holick MF. The vitamin D epidemic and its health consequences. J Nutr 2005; 135: 2739S-2748S.
26. Mosekilde L. Vitamin D and the elderly. Clin Endocrinol (Oxf) 2005; 62: 265-281.
27. Haddad JG. Plasma vitamin D-binding protein (Gc-globulin): multiple tasks. J Steroid Biochem Mol Biol 1995; 53: 579-582.
28. Saramaki A, Banwell CM, Campbell MJ, Carlberg C. Regulation of the human p21 (waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. Nucleic Acids Res 2006; 34: 543-554.
29. Zhang Y, Zhang J, Studzinski GP. AKT pathway is activated by 1, 25-dihydroxyvitamin D3 and participates in its anti-apoptotic effect and cell cycle control in differentiating HL60 cells. Cell Cycle 2006; 5: 447-451.
30. Lundgren S, Carling T, Hjalm G, et al. Tissue distribution of human gp330/megalin, a putative Ca(2+)-sensing protein. J Histochem Cytochem 1997; 45: 383-392.
31. Nykjaer A, Dragun D, Walther D, et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999; 96: 507-515.
32. Brown AJ, Zhong M, Finch J, et al. Rat calcium-sensing receptor is regulated by vitamin D but not by calcium. Am J Physiol 1996; 270: F454-F460.
33. Canaff L, Hendy GN. Human calcium-sensing receptor gene. Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D. J Biol Chem 2002 277: 30337-30350.
34. Brown AJ, Ritter CS, Knutson JC, Strugnell SA. The vitamin D prodrugs 1alpha(OH)D2, 1alpha(OH)D3 and BCI-210 suppress PTH secretion by bovine parathyroid cells. Nephrol Dial Transplant 2006; 21: 644-650.
35. Ritter CS, Armbrecht HJ, Slatopolsky E, Brown AJ. 25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int 2006; 70: 654-659.
36. Canalejo A, Almaden Y, Torregrosa V, et al. The in vitro effect of calcitriol on parathyroid cell proliferation and apoptosis. J Am Soc Nephrol 2000; 11: 1865-1872.
37. Rodriguez M, Canalejo A, Garfia B, Aguilera E, Almaden Y. Pathogenesis of refractory secondary hyperparathyroidism. Kidney Int Suppl. 2002; (80): 155-160.
38. Galitzer H, Ben-Dov I, Lavi-Moshayoff V, Naveh-Many T, Silver J. Fibroblast growth factor 23 acts on the parathyroid to decrease parathyroid hormone secretion. Curr Opin Nephrol Hypertens 2008; 17: 363-367.
39. Inoue Y, Segawa H, Kaneko I, et al. Role of the vitamin D receptor in FGF23 action on phosphate metabolism. Biochem J 2005; 390: 325-331.
40. Krajisnik T, Bjorklund P, Marsell R, et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007; 195: 125-131.
41. Silver J, Naveh-Many T FGF23 and the parathyroid glands. Pediatr Nephrol 2010; 25: 2241-2245.
42. Tebben PJ, Singh RJ, Clarke BL, Kumar R Fibroblast growth factor 23, parathyroid hormone, and 1alpha,25-dihydroxyvitamin D in surgically treated primary hyperparathyroidism. Mayo Clin Proc 2004; 79: 1508-1513.
43. Kobayashi K, Imanishi Y, Miyauchi A, et al. Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur J Endocrinol 2006; 154: 93-99.
44. Yamashita H, Yamashita T, Miyamoto M, et al. Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism. Eur J Endocrinol 2004; 151: 55-60.
45. Silverberg SJ, Bilezikian JP. The diagnosis and management of asymptomatic primary hyperparathyroidism. Nat Clin Pract Endocrinol Metab 2006; 2: 494-503.
46. Silverberg SJ, Shane E, Dempster DW, Bilezikian JP. The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med 1999; 107: 561-567.
47. Lang BH, Lo CY. Vitamin D3 deficiency is associated with late-onset hypocalcemia after minimally invasive parathyroidectomy in a vitamin D borderline area. World J Surg 2010; 34: 1350-1355.
48. Kandil E, Tufaro AP, Carson KA, et al. Correlation of plasma 25-hydroxyvitamin D levels with severity of primary hyperparathyroidism and likelihood of parathyroid adenoma localization on sestamibi scan. Arch Otolaryngol Head Neck Surg 2008; 134: 1071-5.
49. Priya G, Jyotsna VP, Gupta N, et al. Clinical and laboratory profile of primary hyperparathyroidism in India. Postgrad Med J 2008; 84: 34-39.
50. Untch BR, Barfield ME, Dar M, Dixit D, Leight GS, Jr., Olson JA, Jr. Impact of 25-hydroxyvitamin D deficiency on perioperative parathyroid hormone kinetics and results in patients with primary hyperparathyroidism. Surgery 2007; 142: 1022-1026.
51. Beyer TD, Chen EL, Nilubol N, Prinz RA, Solorzano CC. Short-term outcomes of parathyroidectomy in patients with or without 25-hydroxy vitamin D insufficiency. J Surg Res 2007; 143: 145-150.
52. Ozbey N, Erbil Y, Ademoglu E, Ozarmagan S, Barbaros U, Bozbora A. Correlations between vitamin D status and biochemical/clinical and pathological parameters in primary hyperparathyroidism. World J Surg 2006; 30: 321-326.
53. Stewart ZA, Blackford A, Somervell H, et al. 25-hydroxyvitamin D deficiency is a risk factor for symptoms of postoperative hypocalcemia and secondary hyperparathyroidism after minimally invasive parathyroidectomy. Surgery 2005; 138: 1018-1025.
54. Yamashita H, Noguchi S, Uchino S, et al. Vitamin D status in Japanese patients with hyperparathyroidism: seasonal changes and effect on clinical presentation. World J Surg 2002; 26: 937-941.
55. Rao DS, Honasoge M, Divine GW, et al. Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J Clin Endocrinol Metab 2000; 85: 1054-1058.
56. Moosgaard B, Vestergaard P, Heickendorff L, Mosekilde L. Plasma 1,25-dihydroxyvitamin D levels in primary hyperparathyroidism depend on sex, body mass index, plasma phosphate and renal function. Clin Endocrinol (Oxf) 2007; 66: 35-42.
57. Walker MD, Fleischer JB, Di Tullio MR, et al. Cardiac structure and diastolic function in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2010; 95: 2172-2179.
58. Persson A, Bollerslev J, Rosen T, et al. Effect of Surgery on Cardiac Structure and Function in Mild Primary Hyperparathyroidism. Clin Endocrinol (Oxf) 2011; 74(2): 174-180.
59. Forman JP, Giovannucci E, Holmes MD, et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007; 49: 1063-1069.
60. Albright F, Bauer W, Cockrill JR, Ellsworth R. STUDIES ON THE PHYSIOLOGY OF THE PARATHYROID GLANDS: II. The Relation of the Serum Calcium to the Serum Phosphorus at Different Levels of Parathyroid Activity. J Clin Invest 1931; 9: 659-677.
61. Albright F, Bauer W, Claflin D, Cockrill JR. STUDIES IN PARATHYROID PHYSIOLOGY: III. The Effect of Phosphate Ingestion in Clinical Hyperparathyroidism. J Clin Invest 1932; 11: 411-435.
62. Vaishava H, Rizvi SN. Primary hyperparathyroidism associated with nutritional osteomalacia. Am J Med 1969; 46: 640-644.
63. Woodhouse NJ, Doyle FH, Joplin GF Vitamin-D deficiency and primary hyperparathyroidism. Lancet 1971; 2: 283-286.
64. Heath DA, Van't HW, Barnes AD, Gray JG. Value of 1-alpha-hydroxy vitamin D3 in treatment of primary hyperparathyroidism before parathyroidectomy. Br Med J 1979; 1: 450-452.
65. Boyle IT, Fogelman I, Boyce B, Thomson JE, Beastall GH, McIntosh WB, McLennan I. 1alpha-hydroxyvitamin D3 in primary hyperparathyroidism. Clin Endocrinol (Oxf) 1977; 7 Suppl: 215s-222s.
66. Lind L, Wengle B, Sorensen OH, Wide L, Akerstrom G, Ljunghall S. Treatment with active vitamin D (alphacalcidol) in patients with mild primary hyperparathyroidism. Acta Endocrinol (Copenh) 1989; 120: 250-256.
67. Lind L, Wengle B, Lithell H, Ljunghall S. Plasma ionized calcium and cardiovascular risk factors in mild primary hyperparathyroidism: effects of long-term treatment with active vitamin D (alphacalcidol). J Intern Med 1992; 231: 427-432.
68. Patron P, Gardin JP, Borensztein P, Prigent A, Paillard M. Marked direct suppression of primary hyperparathyroidism with osteitis fibrosa cystica by intravenous administration of 1,25-dihydroxycholecalciferol. Miner Electrolyte Metab 1989; 15: 321-325.
69. LoCascio V, Adami S, Galvanini G, Ferrari M, Cominacini L, Tartarotti D) Substrate-product relation of 1-hydroxylase activity in primary hyperparathyroidism. N Engl J Med 1985; 313: 1123-1125.
70. Netelenbos JC, Asscheman H, Lips P, van D, et al. Absence of effect of 24,25-dihydroxyvitamin D3 in primary hyperparathyroidism. J Clin Endocrinol Metab 1986; 63: 246-248.
71. Campbell FC, Xu H, El-Tanani M, Crowe P, Bingham V. The yin and yang of vitamin D receptor (VDR) signaling in neoplastic progression: operational networks and tissue-specific growth control. Biochem Pharmacol 2010; 79: 1-9.
72. Holick MF. Vitamin D: extraskeletal health. Endocrinol Metab Clin North Am 2010; 39: 381-400, table of contents.
73. Grubbs EG, Rafeeq S, Jimenez C, et al. Preoperative vitamin D replacement therapy in primary hyperparathyroidism: safe and beneficial? Surgery 2008; 144: 852-858.
74. Isidro ML, Ruano B. Biochemical effects of calcifediol supplementation in mild, asymptomatic, hyperparathyroidism with concomitant vitamin D deficiency. Endocrine 2009; 36: 305-310.
75. Kantorovich V, Gacad MA, Seeger LL, Adams JS. Bone mineral density increases with vitamin D repletion in patients with coexistent vitamin D insufficiency and primary hyperparathyroidism. J Clin Endocrinol Metab 2000; 85: 3541-3543.
76. Tucci JR. Vitamin D therapy in patients with primary hyperparathyroidism and hypovitaminosis D. Eur J Endocrinol 2009; 161: 189-193.
77. Bilezikian JP, Potts JT, Jr., Fuleihan G, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 2002; 87: 5353-5361.